In the sections that follow, well look at how each medication works, the kind of weightloss results you can expect, the potential side effects, costs, and other factors to consider
La aparicin de los agonistas del receptor del pptido similar al glucagn-1 (GLP-1), como la semaglutida y la tirzepatida, ha generado un debate clnico sin precedentes sobre si estos frmacos pueden desplazar a la ciruga baritrica como el tratamiento definitivo para la obesidad severa
Importantly, the rate of weight regain after discontinuation of medication was faster than after the end of intensive behavioral weightmanagement programs, even when the initial weight loss was similar
Arun Sanyal, M.D., chief of the Division of Gastroenterology, Hepatology and Nutrition and director of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health MASH affects around 15 million Americans, and currently there is only one FDA-approved treatment available, increasing the urgency for effective therapeutic options